相似文献
1
Signaling by Antibodies: Recent Progress.
Annu Rev Immunol. 2017 Apr 26;35:285-311. doi: 10.1146/annurev-immunol-051116-052433.
2
Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches.
J Clin Immunol. 2016 May;36 Suppl 1:83-7. doi: 10.1007/s10875-016-0249-6. Epub 2016 Mar 8.
3
Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review.
Int Immunol. 2017 Jul 1;29(7):319-325. doi: 10.1093/intimm/dxx041.
4
FcgammaRIIB as a modulator of autoimmune disease susceptibility.
Autoimmunity. 2007 Sep;40(6):409-17. doi: 10.1080/08916930701464665.
5
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
Nat Biotechnol. 2005 Oct;23(10):1283-8. doi: 10.1038/nbt1143. Epub 2005 Sep 25.
6
IgG Fc engineering to modulate antibody effector functions.
Protein Cell. 2018 Jan;9(1):63-73. doi: 10.1007/s13238-017-0473-8. Epub 2017 Oct 6.
7
Harnessing Fc receptor biology in the design of therapeutic antibodies.
Curr Opin Immunol. 2016 Jun;40:78-87. doi: 10.1016/j.coi.2016.03.005. Epub 2016 Mar 30.
8
7th International Immunoglobulin Conference: Mechanisms of action.
Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):111. doi: 10.1111/cei.12532.
9
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Int Immunol. 2006 Dec;18(12):1759-69. doi: 10.1093/intimm/dxl110. Epub 2006 Oct 31.
10
In this issue: Antibodies in pathogenesis and management of diseases.
Int Rev Immunol. 2017 Jan 2;36(1):1-2. doi: 10.1080/08830185.2017.1290936.
引用本文的文献
1
Autoreactive immunoglobulin G levels and Fc receptor γ subunit upregulation drive mechanical allodynia after nerve constriction or crush injury.
Pain. 2025 Jul 18. doi: 10.1097/j.pain.0000000000003734.
2
Sub-neutralizing levels of antibodies against RSV F protein enhance RSV infection via Fc-FcγR interactions.
Front Immunol. 2025 Jun 10;16:1594937. doi: 10.3389/fimmu.2025.1594937. eCollection 2025.
3
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
J Hematol Oncol. 2025 Jun 7;18(1):62. doi: 10.1186/s13045-025-01701-6.
4
Monophosphoryl Lipid A-2,4-Dinitrophenylamine Conjugates Are Potent Adjuvants for Carbohydrate and Protein Vaccines.
JACS Au. 2025 Apr 29;5(5):2210-2222. doi: 10.1021/jacsau.5c00187. eCollection 2025 May 26.
5
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab.
Oncoimmunology. 2025 Dec;14(1):2494995. doi: 10.1080/2162402X.2025.2494995. Epub 2025 May 1.
6
Vaccination against influenza viruses annually: Renewing or narrowing the protective shield?
J Exp Med. 2025 Jul 7;222(7). doi: 10.1084/jem.20241283. Epub 2025 Apr 24.
7
Autoreactive IgG levels and Fc receptor γ subunit upregulation drive mechanical allodynia after nerve constriction or crush injury.
bioRxiv. 2025 Mar 24:2025.03.22.644748. doi: 10.1101/2025.03.22.644748.
8
Translational Advances in Oncogene and Tumor-Suppressor Gene Research.
Cancers (Basel). 2025 Mar 17;17(6):1008. doi: 10.3390/cancers17061008.
9
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects.
Front Immunol. 2025 Feb 12;16:1519300. doi: 10.3389/fimmu.2025.1519300. eCollection 2025.
10
Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.
Front Immunol. 2025 Jan 27;15:1502458. doi: 10.3389/fimmu.2024.1502458. eCollection 2024.
本文引用的文献
1
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5944-E5951. doi: 10.1073/pnas.1613225113. Epub 2016 Sep 19.
2
Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses.
Sci Rep. 2016 Jul 6;6:29201. doi: 10.1038/srep29201.
3
Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
Nat Immunol. 2016 Sep;17(9):1102-8. doi: 10.1038/ni.3515. Epub 2016 Jun 23.
4
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen.
PLoS One. 2016 Jun 20;11(6):e0157788. doi: 10.1371/journal.pone.0157788. eCollection 2016.
5
Glycosylation of plasma IgG in colorectal cancer prognosis.
Sci Rep. 2016 Jun 15;6:28098. doi: 10.1038/srep28098.
6
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Cancer Cell. 2016 Jun 13;29(6):820-831. doi: 10.1016/j.ccell.2016.05.001. Epub 2016 Jun 2.
7
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.
Cell Rep. 2016 May 31;15(9):2000-11. doi: 10.1016/j.celrep.2016.04.084. Epub 2016 May 19.
8
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.
9
Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.
mBio. 2016 Apr 19;7(2):e00417-16. doi: 10.1128/mBio.00417-16.
10
Tremelimumab: research and clinical development.
Onco Targets Ther. 2016 Mar 23;9:1767-76. doi: 10.2147/OTT.S65802. eCollection 2016.
Zotero 插件